Ignite Creation Date:
2024-05-06 @ 9:09 AM
Last Modification Date:
2024-10-26 @ 12:10 PM
Study NCT ID:
NCT02916056
Status:
TERMINATED
Last Update Posted:
2021-06-01
First Post:
2016-08-10
Brief Title:
2-Year Extension Study of Azeliragon in Subjects With Alzheimers Disease STEADFAST Extension
Sponsor:
vTv Therapeutics
Organization:
vTv Therapeutics
Study Overview
Official Title:
Open Label Extension Study for Continued Safety and Efficacy Evaluation of Azeliragon in Patients With Mild Alzheimers Disease
Status:
TERMINATED
Status Verified Date:
2021-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not due to safety but due to a lack of efficacy at the 5 mg azeliragon dose
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open-label extension study in patients with mild Alzheimers disease who have completed participation in the azeliragon Phase 3 STEADFAST trial Patients will receive azeliragon 5 mgday for up to 2 years
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None